Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) by Fang Lu et al.
RESEARCH Open Access
Genome-wide analysis of host-chromosome
binding sites for Epstein-Barr Virus Nuclear
Antigen 1 (EBNA1)
Fang Lu1, Priyankara Wikramasinghe1, Julie Norseen1,2, Kevin Tsai1, Pu Wang1, Louise Showe1, Ramana V Davuluri1,
Paul M Lieberman1*
Abstract
The Epstein-Barr Virus (EBV) Nuclear Antigen 1 (EBNA1) protein is required for the establishment of EBV latent
infection in proliferating B-lymphocytes. EBNA1 is a multifunctional DNA-binding protein that stimulates DNA
replication at the viral origin of plasmid replication (OriP), regulates transcription of viral and cellular genes, and
tethers the viral episome to the cellular chromosome. EBNA1 also provides a survival function to B-lymphocytes,
potentially through its ability to alter cellular gene expression. To better understand these various functions of
EBNA1, we performed a genome-wide analysis of the viral and cellular DNA sites associated with EBNA1 protein in
a latently infected Burkitt lymphoma B-cell line. Chromatin-immunoprecipitation (ChIP) combined with massively
parallel deep-sequencing (ChIP-Seq) was used to identify cellular sites bound by EBNA1. Sites identified by ChIP-
Seq were validated by conventional real-time PCR, and ChIP-Seq provided quantitative, high-resolution detection of
the known EBNA1 binding sites on the EBV genome at OriP and Qp. We identified at least one cluster of unusually
high-affinity EBNA1 binding sites on chromosome 11, between the divergent FAM55 D and FAM55B genes. A con-
sensus for all cellular EBNA1 binding sites is distinct from those derived from the known viral binding sites, sug-
gesting that some of these sites are indirectly bound by EBNA1. EBNA1 also bound close to the transcriptional start
sites of a large number of cellular genes, including HDAC3, CDC7, and MAP3K1, which we show are positively
regulated by EBNA1. EBNA1 binding sites were enriched in some repetitive elements, especially LINE 1 retrotran-
sposons, and had weak correlations with histone modifications and ORC binding. We conclude that EBNA1 can
interact with a large number of cellular genes and chromosomal loci in latently infected cells, but that these sites
are likely to represent a complex ensemble of direct and indirect EBNA1 binding sites.
Introduction
Epstein-Barr virus (EBV) is a human lymphotropic gam-
maherpesvirus associated with a spectrum of lymphoid
and epithelial cell malignancies, including Burkitt’s lym-
phoma, Hodgkin’s disease, nasopharyngeal carcinoma, and
post-transplant lymphoproliferative disease (reviewed in
[1,2]). EBV establishes a long-term latent infection in
human B-lymphocytes where it persists as a multicopy
episome that periodically may reactivate and produce pro-
geny virus. During latency the EBV genome expresses a
limited number of viral genes that are required for viral
genome maintenance and host-cell survival. The viral gene
expression pattern during latency can vary depending on
the cell type and its proliferative capacity (reviewed in
[3,4]). Among the latency genes, EBNA1 is the most con-
sistently expressed in all forms of latency and viral-asso-
ciated tumors. EBNA1 is required for the establishment of
episomal latent infection and for the long-term survival of
latently infected cells.
EBNA1 is a nuclear phosphoprotein that binds with
high-affinity to three major DNA sites within the EBV
genome [5](reviewed in [6]). At OriP, EBNA1 binds to
each of the 30 bp elements of the family of repeats (FR),
and to four 18 bp sequences within the dyad symmetry
(DS) element. EBNA1 binding to OriP is essential for
plasmid DNA replication and episome maintenance, and
can also function as a transcriptional enhancer of the C
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promoter (Cp) [7,8]. At the Q promoter (Qp), EBNA1
binds to two 18 bp sequences immediately downstream
of the transcriptional start site, and functions as an inhi-
bitor of transcription initiation and mRNA accumulation
[9]. EBNA1 binds directly to DNA through its C-
terminal DNA binding domain [5,10]. The structure of
the EBNA1 DNA binding domain has been solved by X-
ray crystallography and was found to have structural
similarity to papillomavirus E2 protein DNA binding
domain [11,12]. In addition to direct DNA binding
through the C-terminal domain, EBNA1 tethers the EBV
genome to metaphase chromosomes through its amino
terminal domain [13,14]. The precise chromosomal sites,
proteins, or structures through which EBNA1 attaches
during metaphase are not completely understood [14-16].
Recent studies have revealed that EBNA1 can bind to
and regulate numerous cellular gene promoters [17,18].
Others have identified cellular phenotypes, like genomic
instability, and the genes associated with genomic
instability, to be regulated by ectopic expression of
EBNA1 in non-EBV infected Burkitt lymphoma cell
lines [19]. Overexpression of the EBNA1 DNA binding
domain, which functions as a dominant negative in EBV
infected cells, can inhibit cell viability in uninfected
cells, suggesting that EBNA1 binds to and regulates cel-
lular genes important for cell survival [20]. In more
recent studies, EBNA1 binding was examined at a subset
of cellular sites using predicted promoter arrays. How-
ever, EBNA1 is likely to bind to other regions of the
cellular chromosome that may be important for long-
distance enhancer-promoter interactions, as well as for
regulation of chromatin structure and DNA replication.
To explore these additional possible functions of
EBNA1, we applied Solexa-based deep sequencing meth-
ods to analyze the genome-wide interaction sites of
EBNA1 in latently infected Raji Burkitt lymphoma cells.
Our results corroborate previous studies that demon-
strate multiple cellular promoter binding sites for
EBNA1, and extend these studies to reveal numerous
EBNA1 binding sites not closely linked to a promoter
start site. We conclude that EBNA1 has the potential to
function as a global regulator of cellular gene expression
and chromosome organization, similar to its known
function in the EBV genome.
Results
ChIP-Seq Analysis of EBV and human genomes
Raji Burkitt lymphoma cells were selected for EBNA1-
ChIP-Seq experiments because they maintain a stable
copy number of EBV episomes, and because the gen-
omes are incapable of lytic replication (due to a muta-
tion in BALF2), which might complicate ChIP analysis.
Anti-EBNA1 monoclonal antibody and IgG control
ChIP DNA was analyzed by Solexa-Illumina based deep
sequencing methods. Sequence reads were mapped to
the EBV or human genomes using the UCSC genome
browser http://genome.ucsc.edu/cgi-bin/hgTracks, and a
fold enrichment for EBNA1 relative to IgG control anti-
bodies was calculated. A summary of the sequencing
reads mapped to the human and viral genome is pre-
sented in Table 1. The EBNA1 enriched peaks that
mapped to the EBV genome are shown in Figure 1A.
We found three major peaks for EBNA1 mapping to the
FR, DS and Qp region, as were predicted from earlier
genetic and biochemical studies of EBNA1 binding to
EBV DNA. No other regions were identified, indicating
that these sites are likely to represent the major binding
sites of EBNA1 in Raji genomes in vivo. Interestingly,
the number of reads was greatest at the DS despite the
fact the DNA replication does not consistently initiate
from DS in Raji genomes [21,22]. The DS peak extended
into the adjacent Rep* region, suggesting that these aux-
illary EBNA1 binding sites contribute to the overall sig-
nal observed at the DS region [23]. Importantly, these
results provide validation that EBNA1 ChIP Seq analysis
was consistent with previous biochemical and genetic
studies.
Initial inspection of EBNA1 binding sites across the
human genome revealed a large number of candidate
sites (4785 total sites with 903 showing >10 fold enrich-
ment over IgG and peak score >8) with various posi-
tions relative to transcription start sites. Among the
most remarkable was a cluster of highly enriched
EBNA1 binding sites extending over ~40 kb region in
chromosome 11, within the intergenic region upstream
of the divergent promoters for the FAM55 D and
FAM55B genes (Figure 1B and 1C). Numerous smaller
peaks of EBNA1 binding were found in close proximity
to the start sites of many cellular genes (e.g. MAP3-
K7IP2 and CDC7), as well at alternative promoter start
sites (e.g. HDAC3), and repetitive elements (e.g. LINES)
as shown in Figure 2. The density of EBNA1 peaks
relative to transcription start sites was calculated
(Figure 3A). We found that EBNA1 binding sites with
10 fold enrichment relative to IgG were elevated ~3 fold
at the positions -500 to +500 relative to transcription
start sites. This is consistent with the reported role of
EBNA1 in the regulation of cellular gene expression.
EBNA1 binding sites were also analyzed for overlap
with repetitive DNA elements (Figure 3B). Over 50% of
EBNA1 binding sites overlap with a repetitive element.
LINE elements were the most prevalent sites of overlap
(Figure 2D and 3B). We also found that EBNA1 was
enriched ~2-3 fold at telomere repeat DNA (data not
shown). This was intriguing since other studies have
found evidence for biochemical interactions between
EBNA1 and telomere repeat binding factors, as well as
the incorporation of telomere repeat DNA into the DS
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Table 1 Solexa Sequencing and Genome Mapping Summary
Sample Solexa Illumina Pass Filtered sequence Mapped to Human Genome Mapped to EBV Genome Unmapped
EBNA1 14268722 10783205(75.57%) 123764(0.87%) 3361753(23.56%)
IgG 11961444 8317994(69.54%) 35991(0.30%) 3607459(30.16%)
Figure 1 Example of ChIP-Seq data on EBV genome and host-cell chromosome 11 EBNA1 binding site cluster. The UCSC genome
browser was used to map EBNA1 ChIP-Seq peak files and enrichment beds to the EBV genome (panel A) or human chromosome 11 FAM55B
and D intergenic region at 1 MB (panel B) or 100 kB (panel C) resolution. Wiggle files show the fold enrichment calculated as EBNA1 over IgG,
and the track count for EBNA1. Peaks for family of repeats (FR), dyad symmetry (DS), and Q promoter (Qp) are indicated in red for the EBV
genome (A).
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Figure 2 Example of ChIP Seq data for EBNA1 binding near transcriptional start sites of cellular genes and to a LINE 1 element. The
UCSC browser was used to map EBNA1 peaks, enrichment beds, and Wiggle files to cellular genes for (A) MAP3K7IP2, (B) CDC7, (C) HDAC3, and
(D) a LINE1 repeat. RefSeq annotated transcripts are indicated below each wiggle file.
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region of OriP [24]. We also examined EBNA1 binding
sites for overlap with reported histone modification pat-
terns in lymphoblastoid and fibroblast cell lines from
published ChIP-Seq (Figure 3C) and ChIP-ChIP (Figure
3D) data sets. We found that EBNA1 binding sites are
predicted to overlap with major peaks of H3K4me3
(Figure 3C), but also with broader regions enriched
in histone H3 K27me3, H4K20me1, and H3K9me1
(Figure 3D).
Identification of cellular EBNA1 binding sites in
chromosome 11 and MAP3K7IP2 promoter region
To determine if some of the EBNA1 ChIP-Seq sites
were bound directly by EBNA1, we assayed the ability of
purified EBNA1 protein DNA binding domain (DBD) to
bind candidate sequences in vitro using EMSA (Figure 4).
The high occupancy EBNA1 binding sites throughout
the genome (>10 fold enrichment and peak score >8)
were analyzed using the MEME web application http://
Figure 3 Summary of EBNA1 binding site overlap with annotated genome landmarks. The 903 EBNA1 peaks that were filtered for high-
occupancy (>10 fold enrichment and peak scores >8) were analyzed for overlap with annotated genomic features. A) EBNA1 binding sites (# of
high occupancy peaks) were analyzed for overlap of RefSeq annotated transcription start sites using windows of 500 bp, as indicated in the
X-axis. B) EBNA1 peaks were analyzed for overlap with RefSeq annotations for repetitive DNA elements. Of the 903 total EBNA1 peaks, 410
mapped to repetitive DNA (~45%). Overlaps with various repeats, including LTR, LINE, and SINE elements, are indicated. C) Overlap of EBNA1
with published ChIP-Seq data for histone modifications H3K4me2, H3K4me3, H3K9me2, H3K9me3, and H3K27me3. D) Overlap of EBNA1 binding
sites with UCSC annotated binding sites for CTCF and other histone modifications using ChIP-ChIP data sets.
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meme.nbcr.net/meme4_3_0/cgi-bin/meme.cgi. Several
candidate motifs are shown in Web LOGO format (Fig-
ure 4A), and the most common sequences were synthe-
sized as 40 bp probes for use in EMSA. As a positive
control, we assayed EBNA1 DBD for binding to the
EBV FR DNA (Figure 4B, lanes 1-2). The most signifi-
cant pattern found was a motif (Chr11.1) that was
repeated 41 times in the chromosome 11 cluster. Other
significant motifs (Motifs 2-5) were found scattered
throughout the genome. We found that EBNA1 DBD
bound with relatively high affinity to the Chr11.1 and
Motif 2 (Figure 4B, lanes 2-6), but not to motifs Motifs
3, 4, or 5. We also analyzed the peak sequences
enriched in ChIP Seq analysis at the CDC7, MAP3-
K7IP2, and HDAC3 binding sites (Figure 4B, lanes 13-
18). Surprisingly, we found that only the MAP3K7IP2
binding site bound EBNA1 DBD directly. Other sites
bound with affinities similar to that of a non-specific
control for the EBV ZRE1/2 binding element (Figure 4B,
lanes 19-20). The finding suggest that many of the
EBNA1 peaks in ChIP Seq are either bound indirectly
by EBNA1, or are not centered on the specific DNA
recognition site bound by DNA.
To determine if EBNA1 bound to several distinct
motifs, we rederived the consensus sites for Motif 2
(Figure 4C) and Chr 11 (Figure 4D) using a higher strin-
gency for peak scores >10 and narrower window. We
find that these consensus motifs are significantly differ-
ent from each other and from previously established
binding site consensus from EBV genome sites. The
chr11 motif is found 771 times in the complete human
genome, but is occupied by EBNA1 at only 23 of these
sites (> 8 fold enrichment and peak score > 10). Motif 2
is found 429331 times in the human genome, but is
occupied by EBNA1 at only 74 sites. These finding indi-
cate that EBNA1 can bind directly to multiple cellular
Figure 4 Consensus binding site of EBNA1 at the Chromosome 11 cluster. A) MEME and Web Logo analysis of motifs identified in the
EBNA1 ChIP-Seq peaks. Chr11.1 represents the motif found in the chromosome 11 cluster, while other Motifs (2-5) were scattered throughout
the genome. B) EMSA analysis of 32 P labeled probes containing the EBNA1 peak sites in EBV FR (lanes 1-2), Chr 11.1 (lanes 3-4), Motif 2 (lanes
5-6), Motif 3 (lanes 7-8), Motif 4 (lanes 9-10), Motif 5 (lanes 11-12), CDC7 (lanes 13-14), MAP3K7IP2 (lanes 15-16), HDAC3 (lanes 17-18), or control
EBV ZRE1/2 (lanes 19-20) with (+) or without (-) EBNA1 DBD proteins. Arrow indicates bound form of EBNA1. C) Most frequently observed
consensus motif derived from 903 cellular binding sites using a 20 bp window. D) Most frequent consensus observed in chromosome 11 repeat
using a 20 bp window. E) Most frequent motif overlapping EBNA1 binding sites using a 10 bp window.
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sites in the cellular genome, but actual binding may be
restricted by chromatin context. These findings also
indicate that EBNA1 can recognize a more degenerate
DNA consensus site than previously appreciated. A
similar conclusion was reached by Dresang et al. [17].
We also found that many EBNA1 ChIP-Seq binding
sites were enriched for motifs that could not bind
EBNA1. Among the most significant consensus motifs
that did not bind directly to EBNA1 is shown in Figure
4E. Using search algorithms JASPER and TomTom to
identify potential overlapping transcription factor recog-
nition motifs, we found that Motif 4 contains a consen-
sus Sp1 (p value .0011) and a Staf/Znf123 (p value
.0023) recognition site. The identification of such con-
sensus sites may help to identify cellular factors that
mediate EBNA1 interaction with chromosomes through
indirect mechanisms.
Validation of EBNA1 ChIP binding sites
To determine what percent of the EBNA1 binding sites
determined by ChIP-Seq could be validated by indepen-
dent ChIP analysis using real-time PCR methods, we
assayed 26 independent loci that had varying enrich-
ment signals in ChIP-Seq analysis. As expected, EBNA1
was highly enriched at DS (~4% of input DNA was
recovered). Interestingly, a similar enrichment was
found for the chromosome 11 cluster (Figure 5A).
Almost all of the sites enriched by ChIP-seq were simi-
larly enriched by real-time PCR relative to IgG. Several
regions were not enriched, including those for EBV Ori-
Lyt, and cellular sites for GAPDH, HFM1, PMF1, and
IL6R, which had low enrichment (<10 fold) in ChIP Seq
analysis (Figure 5B and 5C). To determine if EBNA1
enrichment was independent of the monoclonal anti-
body and the cell type, we assayed the binding of
FLAG-EBNA1 after ectopic expression in EBV-293 cells
(Figure 5D). We found that FLAG-EBNA1 bound with
similar pattern and percent enrichment in Flag-EBNA1
transfected cells as did endogenous EBNA1 in Raji cells
(Figure 5C). Similar results were also obtained in EBV
positive lymphoblastoid cell lines (LCLs) (data not
shown). This indicates that our results were not an arti-
fact of the antibody to EBNA1 and not unique to Raji
cells.
Regulation of cellular gene expression by EBNA1
To determine if cellular genes containing EBNA1 binding
sites near the transcriptional start site were regulated by
EBNA1, we assayed the effect of EBNA1 shRNA deple-
tion. Raji cells were transfected with a plasmid expressing
shEBNA1 or control shRNA (shControl), along with a
GFP marker gene, and then selected by FACS for trans-
fected cells (Figure 6). Western blot analysis indicated
that EBNA1 levels were reduced to ~40% of control
levels (Figure 6A) at 96 hrs post-infection. Since EBNA1
is required for Raji cell viability, we also observed a ~2
fold reduction in cell metabolic activity as measured by
MTT assay (Figure 6B). To determine if EBNA1 deple-
tion altered gene expression of any of the EBNA1 bound
genes, we compared the RNA levels of several candidate
genes by RT-PCR (Figure 6C and 6D). For genes with
documented alternative promoter start sites, we gener-
ated primer pairs that would detect initiation at both
transcription start sites. We found that EBNA1 depletion
caused a significant reduction of several mRNAs, includ-
ing HDAC3, MAP3K1, SIVA1, MYO1C, PBX2, NIN
(uc001wyk), WASF2, and MDK. We did not find any
genes that were upregulated by EBNA1 depletion,
suggesting that EBNA1 does not function as a general
transcriptional repressor of these tested genes in Raji
cells. To further test the role of EBNA1 in cellular gene
regulation, we assayed the ability of transiently trans-
fected FLAG-EBNA1 to alter cellular gene transcription
in an EBV negative Burkitt lymphoma cell line DG75
(Figure 7). Using this approach, we found that FLAG-
EBNA1 transfection stimulated expression of CDC7,
HDAC3, MAP3K1, MYO1C, TFEB, and PBX2. RT-PCR
of EBNA1 mRNA was used as a positive control for
EBNA1 expression. These results suggest that EBNA1
can activate a subset of genes when ectopically expressed
in EBV negative Burkitt lymphoma cell lines.
Histone modifications at EBNA1 binding sites
To explore the possibility that EBNA1 may associate
with chromatin enriched in a particular histone tail
modification, we first assayed the overall correlations of
EBNA1 binding sites with reported histone tail modifi-
cations in human lymphoid cells (Figure 3C and 3D).
Based on this first analysis, we selected a set of histone
tail modification-specific antibodies for ChIP assays at
several EBNA1 binding sites identified in Raji cells
(Figure8). We first assayed histone H3K4me2, which has
been previously reported to be elevated at EBNA1 bind-
ing sites in the EBV genome [25]. As expected, we
found that H3K4me2 was highly elevated at DS and Qp
in the EBV genome (Figure 8A). H3K4me2 was also ele-
vated at the cellular EBNA1 binding sites associated
with CDC7 and PTPNB. Histone H4K20me1 was found
to have a relatively high genome-wide correlation with
EBNA1 binding (Figure 3D), and was indeed elevated at
DS and Qp, as well as at the cellular EBNA1 binding
sites associated with CDC7, Chr11, HDAC3, MAP3-
K7IP2, and MAP3K1 (Figure 8B). Histone H3K9me3, a
mark associated with heterochromatin and repetitive
DNA, was found to be highly elevated at the Chr11
repeat cluster (Figure 8C). Histone H3K4me3 and acety-
lated histone H3 (AcH3) and H4 (AcH4), which are
associated with euchromatic and transcriptionally active
Lu et al. Virology Journal 2010, 7:262
http://www.virologyj.com/content/7/1/262
Page 7 of 17
Figure 5 Real-time PCR validation of ChIP-Seq data for EBNA1 binding sites near transcription starts. EBNA1 (black bars) or control IgG
(grey bars) were assayed by ChIP in Raji cells for DNA at the EBV DS or cellular chromosome 11 cluster (A), the peaks found at the transcription
start sites for CDC7, HDAC3, MAP3K7IP2, MAP3K1, IL6R, SIVA1, or negative control GAPDH (B), or EBNA1 peaks within genes for PARKIN, FOXP2,
CDC6, SELK, NEK6, PITPNB, HFM1, EBV-OriLyt, JMJD2C, EEPD1, POU2F, CXCL13, DEK, PMF1, NRXN2, or DPM1/MOCS2. D) 293-EBV cells were
transfected with FLAG-EBNA1 and assayed by ChIP with antibodies to FLAG (black bars) or IgG (grey bars) at the EBV DS, or cellular chromosome
11, CDC7, MAP3K1, IL6R, SIVA1, PARKIN, FOXP2, SELK, NEK6, PITPNB, HFM1, or negative controls for EBV-OriLyt, or cellular GAPDH.
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regions, were elevated at cellular genes for CDC7 and
PTPNB, while MAP3K1, MAP3K7IP2, and HDAC3
were found enriched just in AcH3 and AcH4 (Figure
8D-F). These findings suggest that EBNA1 binding may
correlate with some histone modifications, but in a
manner that is complex and context-dependent.
EBNA1 binding site close to the cMyc-IgG translocation
break point in Raji Burkitt Lymphoma
Raji has a rearranged copy of the c-myc gene adjacent to
the gamma 1 constant region gene of the human immuno-
globulin heavy-chain locus, t(8;14) (q24;q32) [26]. Exami-
nation of EBNA1 binding sites in these translocated
Figure 6 shRNA depletion of EBNA1 causes a loss of transcription of several genes with EBNA1 binding sites. A) Western blot showing
EBNA1 (top panel) and loading control Actin (lower panel) in Raji cells transfected with plasmid expressing shControl or shEBNA1. B) Raji cells
transfected with shControl or shEBNA1 plasmids were selected by GFP positive FACS, and then assayed at 96 hrs post-infection for absorbance
in the presence of metabolic activity indicator MTT. C) shControl (grey) or shEBNA1 (black) infected Raji cells were assayed by RT-PCR for genes
CDC7, HDAC3, MAP3K7IP1, MAP3K, IL6R, or SIVA1. D) Same as in panel C, except at different cellular genes, as indicated in the legend. For genes
with more than one promoter start site, additional primer pairs were used to measure each alternative transcript, as indicated by _1 or _2. All
RT-PCR was normalized with GAPDH.
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regions revealed peaks of >3 fold enrichment at the cMyc
3’ end of chromosome 8 and >10 fold enrichment within
the IgH locus of chromosome 14. In Raji Burkitt lym-
phoma, these two sites are fused together by a breakpoint
in the cMyc and IgH 5’ region, thus bringing the two
EBNA1 binding sites in close proximity in the translocated
allele. Although the mechanism of translocation is
unknown, EBV has been considered a potential driving
force for the Burkitt’s translocations, and it is possible that
these EBNA1 binding sites may link these sites to facilitate
translocation.
Discussion
EBNA1 can interact with a large number of cellular
binding sites
In this study, we used ChIP-Seq to identify ~903 high
occupancy (>10 fold enrichment and peak score >8),
and ~4300 moderate occupancy (>3 fold enrichment
and peak score >5) binding sites for EBNA1 in the cellu-
lar chromosome of a human Burkitt lymphoma cell line.
Several (~25) of the high and low occupancy binding
sites identified by ChIP-Seq were validated for binding
by conventional ChIP and real-time PCR (Figure 5).
Figure 7 Ectopic expression of EBNA1 activates a subset of genes with EBNA1 binding sites. EBV negative Burkitt lymphoma cell line
DG75 was transfected with Control vector (grey bars) or with FLAG-EBNA1 (black bars) expression vector and than assayed 48 hrs post-
transfection by RT-PCR for A) CDC7, HDAC3, MAP3K7IP2, MAP3K1, IL6R, SIVA1, or control EBNA1, and for B) AKNA, MYO1C, N4BP1, TFEB, GPAM,
PBX2, NIN, WASF2, and MDK, as indicated.
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Figure 8 Histone modifications associated with EBNA1 binding sites. Raji cells were assayed by ChIP using control IgG (greay bars) or
modification-specific antibodies (black bars) for (A) H3K4me2, (B) H4K20me1, (C) H3K9me3, (D) H3K4me3, (E) AcH3, and (F) AcH4 at EBNA1
binding sites in EBV DS and Qp, or cellular CDC7, Chr11, HDAC3, MAP3K7IP2, MAP3K1 or PITPNB. ChIP DNA was quantified by real-time PCR as
percent of input DNA.
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There was a good correlation between ChIP-Seq and
ChIP-PCR for these binding sites, providing a high level
of confidence in the ChIP-Seq data. Furthermore, only
bonafide EBNA1 binding sites in the EBV genome (FR,
DS, and Qp) scored positive in ChIP-Seq analysis (Fig-
ure 1A), suggesting that few false positives were gener-
ated by this method. Among the high-occupancy
binding sites, we noted that ~7% are located within 500
bp of an annotated or predicted transcription start site
(Figure 3A). We also noted that ~45% of EBNA1 bind-
ing sites overlapped with a repetitive DNA element
(Figure 3B). Several DNA motifs could be identified in
the high-occupancy EBNA1 binding site data set, but
only two of these were found to bind directly to recom-
binant EBNA1 protein in vitro (Figure 4). Since EBNA1
is known to bind DNA directly through its carboxy-
terminal DNA binding domain, and indirectly through
its amino terminal tethering domain, it seems likely that
many of the binding sites identified by ChIP-Seq repre-
sent a composite of these direct and indirect DNA-
binding modes of EBNA1.
Identification of high affinity cellular binding sites
A remarkable finding from this study was the identifica-
tion of a cluster of high-affinity EBNA1 binding sites in
chromosome 11. The cluster represents ~10 kb of repe-
titive sequence situated between the divergent promo-
ters for the Fam55B and Fam55 D genes. The function
of the Fam55B and D proteins is not known, and
shRNA depletion of EBNA1 had no detectable effect on
Fam55B or D gene transcription. This region was ele-
vated in histone H3 K9me3 (Figure 8) suggesting that it
is largely heterochromatic and unlikely to be involved in
transcription activation. We considered whether this site
may represent a cellular origin of DNA replication, but
we were unable to identify ORC2 or MCM protein
Table 2 EBNA1 binding sites close to RefSeq genes
Chr Start End Motif RefSeq gene hit Dist. to hit
chr1 52074635 52074636 Motif 5 NR_031580 MIR761 500
chr1 91738595 91738596 Motif 3 NM_001134419 CDC7 500
chr1 91739305 91739306 Motif 5 NM_001134420 CDC7 500
chr1 154170655 154170656 NM_014949 KIAA0907 500
chr10 61338790 61338791 Motif 2 NM_005436 CCDC6 3000
chr11 6421695 6421696 NM_000613 HPX 4000
chr12 67007430 67007431 NM_017440 MDM1 5000
chr12 108693660 108693661 Motif 2 NR_026661 MGC14436 4000
chr13 35769560 35769561 Motif 2 NM_001144985 C13orf38 500
chr13 35769000 35769001 NM_001144985 C13orf38 2000
chr14 50358425 50358426 Motif 5 NM_016350 NIN 3000
chr14 23969975 23969976 Motif 4.Motif 5 NM_015299 KHNYN 2000
chr14 104287630 104287631 Motif 5 NM_021709 SIVA1 4000
chr15 26999285 26999286 NM_001130414 APBA2 3000
chr16 3222305 3222306 NM_001145447 ZNF200 4000
chr16 3221595 3221596 NM_001145447 ZNF200 4000
chr17 71770850 71770851 Motif 2 NM_182565 FAM100B 4000
chr17 1335740 1335741 Motif 4 NM_001080950 MYO1C 500
chr17 58917775 58917776 Motif 2.Motif 5 NM_152830 ACE 3000
chr17 64015725 64015726 NM_212471 PRKAR1A 4000
chr2 190751405 190751406 Motif 5 NM_001042519 C2orf88 4000
chr20 49008975 49008976 Motif 2 NM_014484 MOCS3 500
chr20 36872330 36872331 Motif 2.Motif 5 NM_015568 PPP1R16B 5000
chr22 26645510 26645511 NR_026962 LOC284900 500
chr3 75761660 75761661 NR_031714 MIR1324 2000
chr6 18376590 18376591 NM_001134709 DEK 4000
chr6 149683865 149683866 Motif 5 NM_015093 MAP3K7IP2 4000
chr6 39190140 39190141 NM_018322 C6orf64 2000
chrX 41428495 41428496 Motif 2 NM_001097579 GPR34 5000
Each hit peak in the ChIP-seq enrichment list was labeled with our consensus motifs that lay within 50 nts upstream or downstream of the peak site. This
annotated dataset was then used to search for overlaps with a list of RefSeq genes downloaded from the UCSC table browser. This overlap search was done
with a Python script from Priyankara Wickramasinghe (Wistar Institute). Genes whose TSS lie within a distance of 500, 1000, 2000, 3000, 4000, and 5000 nt from
EBNA1 ChIP-seq peaks were subsequently annotated on to the annotated hit peak list. The Galaxy suite http://main.g2.bx.psu.edu/ was used to combine and
organize the various data lists in each step.
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binding at this site (data not shown). Purified EBNA1
DBD protein bound with high affinity to the major
repeat elements in the chromosome 11 cluster, indicat-
ing that the binding is direct and mediated by the
EBNA1 DNA binding domain. At present, it is not clear
whether EBNA1 binding to this region of chromosome
11 has any functional significance.
Novel EBNA1 binding sites
Position weighted matrix (PWM) analysis and Web
LOGO presentation revealed that many cellular EBNA1
binding sites are distinct from the consensus sites
observed at EBV genome binding sites found at the FR,
DS, or Qp regions. The chromosome 11 binding site
consensus TGG[g/a]TAA[T/C][A/C]A[g/c]TGTT[G/A]
CCT and the Motif 2 GG[C/T]AGCAtaT[A/G]CT[A/T]
[T/C]C do not resemble the consensus derived for pre-
viously known EBNA1 binding sites in the viral genome.
However, our Motif 2 is similar the new consensus G
[A/G][T/C]AGcATaTGCTaCC derived by Dresang et al
using 70 viral and cellular binding sites [17]. In a sepa-
rate study, Canaan et al. identified GaA[G/A]TAT[T/C]
as a consensus site for EBNA1 binding at cellular genes
subject to EBNA1 dependent regulation and association
with EBNA1 protein by ChIP [18]. However, it was not
clear from the Canaan et al. study whether these binding
sites are bound directly or indirectly by the EBNA1
DNA binding domain. We also identified several motifs
enriched in the EBNA1 ChIP-Seq peaks that did not
bind directly to EBNA1 DNA binding domain in vitro.
These sites may reflect indirect DNA binding by
EBNA1, potentially through interactions with other
sequence specific factors or chromatin-associated pro-
teins. Cellular factors that have been implicated in med-
iating EBNA1 tethering to metaphase chromosomes,
including EBP2 [27-29], histone H1 [16], and HMGA1
[14,30], may be good candidates for interactions with
some of these indirect binding motifs. In the future, it
will be important to determine if there are functional
differences between these different classes of EBNA1
binding sites, and what cellular factors mediate the
indirect binding of EBNA1 to cellular chromosomes.
EBNA1 regulated cellular genes
Ectopic expression of EBNA1 has been shown to regu-
late several cellular genes, including NOX2 in Ramos
[19], and the chemokines CCL4, CCL3, and CCL18 in
BJAB cells [18]. Dresang et al. identified and confirmed
direct binding of EBNA1 to several cellular promoters,
but could not confirm that these were indeed EBNA1-
responsive promoters in plasmid based reporter assays
[17]. These previous studies identified ~366 cellular
genes as potential targets of EBNA1. In our study, we
considered only 36 candidate cellular genes that have
highly enriched (peak score > 8 and enrichment >10)
EBNA1 binding sites within 500 bp of the transcrip-
tional start site (Table 2). Of these 36, only four genes
were common to the previous studies, namely MOCS3,
CDC7, TTC7A, and FGB. However, lower threshold
EBNA1 (peak score >3 and enrichment >3) binding sites
were observed at many of the sites identified by Dresang
et al., including binding sites upstream of SELK, IL6R,
MKI67, and MYO5B. We did not find significant
enrichment of EBNA1 at NOX2 or CCL4. Some of
these discrepancies may be a result of differences in cell
types used for each experiment. Different cell types, as
well as differentiation states, may restrict EBNA1 bind-
ing through changes in chromatin structure or epige-
netic modifications. We found some evidence that
EBNA1 binding sites correlated with histone modifica-
tions, namely the euchromatin-associated H3K4me3 and
H3K4me2 (Figure 3C). However, this analysis is limited
since the histone modifications were analyzed in EBNA1
negative T-cells [31], and not in the same Raji cells as
EBNA1 ChIP Seq experiments were performed. A
small-scale analysis of confirmed EBNA1 binding sites
in Raji cells revealed a complex correlation with histone
modifications (Figure 8), suggesting that EBNA1 can
bind to various chromatin structures. However, addi-
tional studies of EBNA1 and histone modification co-oc-
cupancy are required to determine whether EBNA1
binding sites have a common chromatin environment.
EBNA1 may regulate to chromosome structure
The large number of direct and indirect EBNA1 binding
sites distal to transcription start sites suggests that
EBNA1 may be involved in modulating chromosome
structure. EBNA1 is known to mediate long-distance
interactions important for transcription of Cp during
EBV infection of primary B-cells [8]. EBNA1 is also
known to form highly stable homotypic interactions
through its linking domains [32], which are thought to
play important roles in tethering EBV episomes to meta-
phase chromosomes [33]. EBNA1 has also been a sus-
pect in EBV-associated lymphomagenesis, especially
Burkitt lymphoma where EBNA1 is expressed early and
consistently throughout cancer cell evolution. Our
ChIP-Seq data revealed that EBNA1 can bind to regions
close to the chromosomal translocation break-points in
both cMyc and IgG heavy chain enhancer regions
(Figure 9), which represents the defining translocation
associated with Burkitt’s lymphoma. This provides a
potential mechanism for EBNA1 in facilitating chromo-
some translocation by potentially mediating an interac-
tion between these two loci. Further studies will be
required to determine whether EBNA1 binding can
mediate interactions between these two chromosomal
sites in Burkitt’s and non-Burkitt’s lymphoma cells, and
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whether EBNA1 mediates long-distance interactions
between other cellular and viral chromosomal sites iden-
tified in this study.
Methods
Cells and Plasmids
Raji cells (human EBV positive Burkitt lymphoma line)
and DG75 (human EBV negative Burkitt lymphoma
line) were maintained in RPMI containing 10% FBS and
supplemented with glutamax (Invtitrogen) and antibio-
tics (penicillin and streptomycin). EBV-293 contains a
hygromycin resistant EBV bacmid in human embryonic
kidney (HEK) 293 cells (a kind gift of H. Delecluse)
were maintained in RPMI containing 10% FBS, hygro-
mycin (100 μg/ml), glutamax, and antibiotics. pCMV-
Flag-EBNA1 was previously described [15]. shRNA
directed against EBNA1 was generated by cloning the
targeting hairpin sequence (gatatgtctcccctccctcctaggc
cactcaagcttcaatggcctaggagagaagggagacacatc) into the
pENTR/D-Topo vector (Invitrogen).
Chromatin immunoprecipitation (ChIP) Assays
ChIP assays were performed as described previously [34].
Quantification of precipitated DNA was determined
using real-time PCR and the standard curve method for
absolute quantitation (ABI 7000 Real-Time PCR System).
IPs were performed in triplicate for each antibody and
the PCR reactions were repeated at least three times and
standard deviations were indicated by error bars. Primers
for ChIP assays are listed in Additional File 1 in the
online Data Supplement. The following rabbit polyclonal
antibodies were used for ChIP assays: anti-EBNA1 (305/
10 wk), anti-IgG (Santa Cruz Biotechnology), anti-Flag
(Sigma), anti-Acetylated histone H3 and H4 (Millipore),
anti-dimethylated histone H3K4 (Abcam), anti mono-
methylated H4k20 (Abcam), and anti-trimethyl histone
Figure 9 EBNA1 binding site near the point of cMyc-IgG translocation in Raji Burkitt lymphoma cells. EBNA1 wiggle tracks and peak bed
enrichment from UCSC browser of the translocation regions at the chromosome 8 cMyc locus (A) and the chromosome 14 IgH gene locus (B).
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H3K9 and H3K4 (Millipore). Mouse monoclonal anti-
actin (Sigma) and anti-EBNA1 (Advance Biotechnology)
were used for Western Blotting.
Quantitative RT-PCR
Briefly, RNA was isolated from 2 × 105 cells using
RNeasy Kit (Qiagen) and then further treated with
DNase I. Reverse transcriptase PCR (RT-PCR) was done
as previously described. Real-time PCR was performed
with SYBR green probe in an ABI Prism 7000 according
to the manufacturer’s specified parameters. Primer
sequences for RT-PCR are listed in Additional File 2.
MTT assay
1 × 104 Raji cells were plated in 96-well plates at 96 hrs
post-transfection of shEBNA1 or Control shRNA. Cell
viability was then measured by incorporation of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) (Millipore, Cell Growth Assay Kit), according to
the manufacturer’s protocol.
EMSA
Purified EBNA1 DNA binding domain (DBD) (aa 459-
607) was expressed and purified from E. coli as a hexa-
histidine fusion protein in Escherichia coli.
Protein-DNA binding reactions contained 10% Gly-
cerol, 200 mM NaCl, 20 mM Tris-Cl pH 7.4, 1 mM
DTT, 10 μg/mL BSA, 10 nM 32P-labeled oligonucleotide
DNA and 246 nM purified EBNA1 DBD. Samples were
incubated for 20 min at 25°C then loaded onto a 6%
polyacrylamide gel and electrophoresed for 90 minutes
at 170 V in 1× TBE. Gels were dried and visualized by
PhosphorImager. Oligonucleotides used for EMSA are
listed in Additional File 3.
Chromatin-Immunoprecipitation for High Throughput
Sequencing (ChIP-Seq)
Solexa ChIP-Seq experiments were performed with 2 ×
106 Raji cells per IP with either EBNA1 monoclonal
antibody or control mouse IgG. ChIP methods were
identical to conventional ChIP assays [34] with the
exception that competitor salmon sperm DNA was
excluded from all IP and wash buffers, and purified
ChIP DNA was resuspended in 25 dH2O. DNA frag-
ments of ~150-300 bp range were isolated by agarose
gel purification, ligated to primers, and then subject to
Solexa sequencing using manufacturers recommenda-
tions (Illumina, Inc.).
Bioinformatics Analysis of ChIP-Seq
Sequencing
Image analysis and base calling of ChIP-seq data was
performed using Illumina pipeline software version 1.4.
Sequence alignment to the human genome hg18 was
done using Illumina casava_1.4 module. Uniquely
aligned sequence tags, with up to two mismatches, were
taken for the downstream analysis.
Peak Calling
A combination of fold ratio and Poisson model for the
tag distribution [35] was used to define peaks as follows:
(i) Identification of genomic regions (of length 1000 bp)
enriched with ChIP-seq sequence tags using fold ratio -
A genomic region is considered as sequence enriched if
the fold ratio, calculated using number of reads normal-
ized to the total reads within that region in ChIP (anti-
body treatment) sample divided by the number of reads
normalized to the total reads in control sample (IgG
control) in the same region, is higher than the given
cutoff. Nearby enriched regions were merged to make
broader enriched genomic regions. A cutoff of 3 was
applied to find the initial genomic regions of enrichment
at this stage. (ii) Creating the read overlapping profile
for each identified region from step 1, by extending the
sequence reads from the 5’ end to the 3’ end of the
reads up to 300 bps (the average length of the ChIP-
DNA fragment sequenced from the Solexa GA with Illu-
mina standard ChIP-seq protocol) for the experiment
sample. (iii) Peak identification, by using Poisson model
- by counting the number of overlapped reads at each
nucleotide position and defining the genomic position
with the highest number as the peak position within the
significant region. Finally, only those genomic regions
that have fold ration > 10 and peak score > 8 and
p value < 0.001 (as determined by Poisson background
model) are considered as statistically significant. Peak
score is calculated as the average value of raw counts
within a given region of significant fold enrichment rela-
tive to control IgG levels. The average is measured for
overlapping tags at every base after extending the tags
to their average tag length within the significant region.
Overlapping of TSS with Peak
For annotating the ChIP-seq peaks, we referred to gene
information tracks from various sources available at
UCSC genome browser. The tracks include Refseq gene,
UCSC gene, Ensembl gene, and Vega gene. Every peak
was annotated to the closest TSS regardless whether the
peak is residing upstream or downstream to the TSS. Fig-
ure 3A shows the distribution of ChIP-seq peaks relative
to the TSSs. We then selected a subset of ChIP-seq
peaks, such that the peaks are within ± 500 bp around
TSS. We call these peaks as TSS associated peaks. Over-
lap with specific genes is provided in Table 2.
Overlapping of repeats with Peak
Repeat region files were downloaded from UCSC gen-
ome browser. All those peaks that fall in repetitive
regions are annotated according to the type of repetitive
region. Same method was used in finding the overlap of
peaks with the repeat sub categories.
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EBNA1 binding Motif Identification
We selected only the highly enriched genomic regions
(enriched region fold ratio > 10 and peak score > 8) for
motif identification. A sequence window of 60 bp
around each peak was used for motif searching. We
applied MEME online version to find the statistically
significant sequence motifs [36,37] http://meme.nbcr.
net/meme4_4_0/intro.html. Possible EBNA1 binding
motifs were predicted based on highest number of
occurrence with the lowest p-value under “zero or one
per sequence” option. Position weighted natrix (PWM)
generated by MEME were then represented in the logo
format by using Web Logo http://weblogo.berkeley.edu/
logo.cgi to generate consensus sequences for multiple
cellular EBNA1 binding sites. PWMs of the motifs iden-
tified by MEME were matched with the JASPER core
database http://jaspar.genereg.net/ using the TOMTOM
program http://meme.nbcr.net/meme4_3_0/cgi-bin/tom-
tom.cgi with a q-value significance (false discovery rate)
threshold of under 0.5.
Overlap of histone modification and EBNA1 peaks
H3K4me2, me3 and H3K9me2, me3 ChIP-seq datasets
were downloaded from NCBI GEO and SRA databases,
published in [31,38]. The accession numbers for the
datasets are as follow: SRX000147, SRX000148,
SRX000153, SRX000154, and GSM325898. Each ChIP-
seq dataset was processed at p < 0.001 using Poisson
background model. A histone modification mark is con-
sidered as overlapping with EBNA1 peak if it falls
within ± 1000 bp around the EBNA1 peak.
Additional material
Additional file 1: Primers usee for validation of ChIP-Seq.
Additional file 2: Primers used for RT-PCR.
Additional file 3: Primers used for EMSA probes.
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